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ABSTRACT  
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage-
ment of high grade gliomas (HGG), with a median overall survival of less than 4 months 
(m). This study evaluated the efficacy of fractionated stereotactic re-irradiation (FSRT) 
for patients with HGG after progression on Bevacizumab.
Materials/Methods: Retrospective review was conducted of patients treated with 
FSRT after progression on bevacizumab. A total of 36 patients were identified. FSRT 
was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival 
from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as 
study endpoints. Univariate and multivariate analysis was performed.
Results: Among the 36 patients, 31 patients had recurrent glioblastoma, and 5 patients 
had recurrent anaplastic astrocytoma. The median time from initial bevacizumab 
treatment to FSRT was 8.5 m (range 2.3 – 32.0 m). The median plan target volume for 
FSRT was 27.5 cc (range 1.95 – 165 cc). With a median follow up of 20.4 m, the overall 
survival of the patients since initial diagnosis was also 24.9 m. The median overall 
survival after initiation of bevacizumab was 13.4 months. The median overall survival 
from FSRT was 4.8 m. FSRT treatment was well tolerated with no Grade >3 toxicity.
Conclusions: Favorable outcomes were observed in patients with recurrent HGG 
who received salvage FSRT after bevacizumab failure. The treatment was well 
tolerated. Prospective study is warranted to further evaluate the efficacy of salvage 
FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed 
bevacizumab treatment.
INTRODUCTION 
Malignant gliomas are the most common 
brain tumors, with an estimated yearly 
incidence of 3 per 100,000 people in the 
United States.1 Despite multiple modali-
ties for definitive therapy (which include 
resection, radiation therapy (RT) and 
chemotherapy), these lesions have an 
unfortunately high rate of recurrence.2 
Therefore, even despite recent treat-
ment advances in targeted therapies 
for glioblastoma (GBM) and high grade 
glioma (HGG) such as bevacizumab, the 
long-term outcomes for these patients 
remain poor. 
In modern clinical practice, treatment 
failure of recurrent HGGs largely repre-
sents failure of bevacizumab therapy.3 
In addition to disease recurrence itself 
driving poor outcomes, there is evidence 
that these patients who fail bevacizumab 
also harbor disease that is resistant to 
other systemic therapies.4 Therefore, 
treatment options for these recurrent 
patients remain limited and their prog-
nosis is dismal with a recent review of 
sixteen studies reporting an overall 
survival (OS) of under 4 months after 
bevacizumab failure.4-6
Multiple modalities of radiotherapy have 
been investigated for this population, 
including stereotactic radiosurgery (SRS) 
and brachytherapy. These interventions 
have been shown to have modest utility, 
but with the potential for significant 
associated toxicity. In that context, frac-
tionated stereotactic radiotherapy (FSRT) 
is a promising treatment modality for the 
treatment of these refractory HGGs. This 
modality possesses the precise targeting 
advantages of SRS but with the dose-
sparing radiobiologic properties of 
fractionation to allow greater sparing 
of surrounding critical structures, thus 
limiting toxicity.7,8 Taken together, 
FSRT therefore possesses the potential 
for decreased toxicity as compared to 
SRS while still providing excellent local 
control.9 The present study sought 
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(intensity modulated radiation therapy) or 
hybrid-Arcs (Brainlab, Munich, Germany), 
a combination of dynamic arcs with IMRT 
beams. The patients were treated with 
FSRT to a median PTV dose of 35 Gy 
delivered in 3.5 Gy fractions.10 The dose 
was reduced to 30 Gy in 3 Gy fractions 
for large targets, and high critical normal 
structure dose. The constraints for normal 
critical structures include: brainstem max 
dose <20 Gy; optic nerve max dose < 15 
Gy, chiasm max dose < 15 Gy. 
Statistical analysis 
The primary end point of the study was 
overall survival from initial diagnosis, as 
well as survival from first recurrence and 
re-irradiation (described in greater detail 
under Statistical Analyses). Toxicity was 
also graded using Radiation Therapy 
Oncology Group (RTOG) criteria. Overall 
survival was defined as the time from 
initial diagnosis to the time of death. Date 
of recurrence was defined as the date of 
radiographic evidence of progression. 
Survival from recurrence and from reir-
radiation were therefore defined as the 
time from this radiologic evidence or 
radiation therapy until death, respectively. 
Kaplan–Meier curves were generated for 
the overall survival endpoint. Cox propor-
tional hazard modeling was used for 
multivariate analysis with factors analyzed 
in a step-wise fashion. All statistical anal-
ysis was performed using the STATA data 
analysis and statistical software version 
13.1 (STATA Corporation).
to evaluate the safety and efficacy of 




The Thomas Jefferson University insti-
tutional review board approved this 
single-institution, retrospective study. 
Patients who received FSRT salvage 
after progression on bevacizumab were 
included. A total of 36 patients were iden-
tified from 2006 to 2013. Patients who 
received FSRT within 2 months of initiation 
of bevacizumab were excluded. Patients 
were followed with MRI scans and clinical 
assessment, which were obtained 6 to 8 
weeks after FSRT and at approximately 
2-month intervals thereafter.  
Treatment Planning 
Treatment decisions were based on 
consensus recommendations following 
discussion in our institution’s multidisci-
plinary brain tumor board consisting of 
radiologists, neurosurgeons, neuro-oncol-
ogists, neuropathologists and radiation 
oncologists. Prior to 2004, treatment plan-
ning was conducted with the X-knife 3-D 
planning system (Radionics, Burlington, 
MA, USA), which delivered 6 MV photons 
with a dedicated stereotactic 600SR linear 
accelerator (Varian, Palo Alto, CA, USA). 
From 2004 to 2013, treatment planning 
was carried out with Brain Lab (Novalis) 
using mMLC leaves with a leave thickness 
of 3 mm and Exac Trac on board imaging. 
All patients undergoing irradiation were 
fitted with custom-made Brainlab (Munich, 
Germany) thermal plastic masks for 
immobilization. Treatment planning MRI 
and computed tomography (CT) images 
were obtained and fused. All patients had 
thin cut (1-1.5 mm) fat suppressed coronal 
post-contrast MRI. The gross tumor 
volume (GTV) was defined on MRI using 
the gadolinium enhanced T1 weighted 
series, as peripherally enhancing tissue. 
Surrounding edema was not purposely 
included in the treatment volume. The 
planning target volume was the GTV with 
minimum margin (0-2 mm per the treating 
physician). Critical normal structures, such 
as optic nerves, chiasm, and brainstem 
were also contoured. Treatment plan-
ning was carried out with Brain Lab Iplan 
(Munich, Germany). The radiation plan-
ning used dynamic conformal arcs, IMRT 
JHN JOURNAL 
RESULTS
Patient Population and Treatment 
Parameters
We identified 36 patients with either 
anaplastic astrocytoma (5 patients) or 
glioblastoma multiforme (GBM) (30 
patients) who had clinical and radio-
graphic evidence of tumor progression on 
bevacizumab and received FSRT between 
2006 and 2013 (Table 1). One patient 
had gemistocytic astrocytoma. Patient 
characteristics are listed in Table 1. There 
were 17 males and 19 females. All patients 
received initial surgery and were treated 
with radiation and temozolomide. The 
median age at recurrence was 57.1 years 
(range 37-73). The median Karnofsky 
Performance Status at recurrence was 
80%. Following disease progression on 
bevacizumab, the median target volume 
treated with FSRT was 27.5 cc (range 
1.95 – 165 cc). The median dose was 
35 Gy (range, 30 Gy – 37.5 Gy). 
Survival
Patients underwent routine surveillance 
for a median follow up of 20.4 m after 
initial diagnosis, with an overall survival 
from initial diagnosis of 24.9 m. Upon 
evidence of initial disease recurrence, 
patients were promptly started on beva-
cizumab. The median overall survival 
after initiation of bevacizumab was 13.4 
months. The median time from initial 
bevacizumab treatment to initiation of 
Table 1.  Patient Demographic and Treatment Information. Descriptive data on our study cohort is 
shown, encompassing demographic data, clinical information and treatment information.




Median Age at FSRT salvage (range) 56 years (37-73)
Median KPS at FSRT salvage (range) 80 (50-100)
Histology at Recurrence
GBM 30
Anaplastic glioma 4 (3-4)
Other 2 (1-2)
Median Volume of Recurrence (range) 27.5 cc (1.95-165)
Median Radiation Dose (range) 35 Gy (30-37.5)
Median time from Bev to FSRT (range) (2.4-32.1)
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in patients with high-grade gliomas, 
treatment failure and disease progres-
sion while on bevacizumab remain as 
an unfortunate reality in managing these 
patients. Therefore, overall prognosis 
remains quite poor.  Despite this clinical 
need, there remains a paucity of literature 
regarding the management of patients 
who fail bevacizumab. In that context, 
the present study investigated FSRT as a 
potential treatment modality to address 
this problem.
Prior to FDA-approval of bevacizumab, 
FSRT had been previously studied in the 
setting of recurrent HGG, with generally 
favorable results. Multiple studies have 
shown FSRT to be efficacious, with OS in 
these studies ranging from 5-11 months. 
Moreover, these studies showed FSRT to 
be very well tolerated, with a low rate of 
grade 3 toxicities, radiation necrosis (RN) 
and reoperation.10-12
Of note, one study (Lederman et al.) 
observed significantly more toxicity and 
reoperation (11 of 88 patients) than the 
others. This toxicity outlier can perhaps 
be explained by the use of a different 
dosing regimen (24 Gy in 4 fractions in 
Lederman et al. versus 30-35 Gy in 6-10 
fractions in the other studies).13  In a head 
to head trial, Patel et al. compared stereo-
tactic radiosurgery (SRS) with FSRT and 
showed comparable overall survival and 
radiographic tumor response between 
the two modalities, with a trend towards 
fewer events of radiation necrosis (RN) in 
the FSRT cohort.14
The data on FSRT treatment following 
bevacizumab failure is much more 
limited. In a retrospective study, Torcu-
ator et al. looked at two cohorts of 
patients who failed bevacizumab: one 
that received either FSRT or SRS and one 
that received no FSRT/SRS. They demon-
strated an increased overall survival in 
patients receiving FSRT/SRS (7.2 vs 3.3 
months in untreated patients). Another 
study that is published only in abstract 
form by Nehaw et al. similarly looked at 
RT (including 6 patients who received 
FSRT) versus non-RT regimens following 
bevacizumab failure and showed statisti-
cally significant increased survival in the 
radiation group (8.8 vs. 5.4 months for 
untreated). Despite this small body of 
literature, neither of these studies inves-
tigated FSRT alone after bevacizumab 
p=0.04). Additionally, there was a trend 
towards significance for re-resection 
status associated with OS from FSRT (HR 
1.87 p=0.17).
Toxicity
No patients demonstrated clinically 
significant acute morbidity, with no grade 
III or higher toxicity observed. All patients 
were able to complete the prescribed 
radiation course without interruption. 
There were no observed hospitalizations 
or surgeries for early acute or delayed 
toxicity in the study population. 
DISCUSSION
Despite recent advances such as bevaci-
zumab that have extended overall survival 
salvage FSRT was 8.5 m (range 2.4 – 32 m), 
and the median overall survival after FSRT 
was 4.8 m. Data are presented in table form 
(Table 2) as well as in the form of a Kaplan-
Meyer survival curve (Figure 1).
Multivariate Analysis
Multivariate analysis was performed to 
investigate whether different variables 
in our study population influenced OS 
from recurrence or from FSRT therapy 
(Table 3). These included age at recur-
rence, KPS score, volume of recurrence, 
histology (AA vs GBM) or re-resection 
status. Importantly, out of all of these 
variables, only re-resection demonstrated 
a statistically significant association with 
overall survival from recurrence (HR 2.59; 
Figure 1.  Kaplan-Meyer Overall Survival Curve. 
Graph displays OS from the time diagnosis for patients who went on to fail bevacizumab 
therapy and require FSRT in our study cohort.














Table 2.  Survival Statistics. Survival data accrued from the study cohort is shown, expressed as 
OS from diagnosis, recurrence and from FSRT. 
Median Overall Survival (Range)
From Diagnosis 24.9 months (11.4-94.2)
From First Recurrence 12.0 months (4.2-49.1)
From FSRT 4.8 months (0.5-23.4)
3
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failure, nor did they report on safety or 
toxicity of these approaches. 
In that context, the present study 
represents one of the first studies 
to specifically investigate the role of 
FSRT in the context of bevacizumab 
failure. Indeed, our work builds off of 
previous work by both our group and 
others showing comparable benefit and 
improved safety in FSRT regimens for 
HGGs as compared to SRS for treatment 
of HGG in other contexts.10,11,13 Specifi-
cally, the present study demonstrates 
the feasibility, efficacy and tolerability 
of such an approach in patients who fail 
bevacizumab. 
One limitation of our study is the lack of 
a control cohort for comparison in terms 
of outcomes to put our overall survival 
into context. Historically, patients who 
fail bevacizumab have been shown in a 
recent review of sixteen studies to have 
an overall survival of 3.8 months.4-6 
Thus, our observed overall survival 
compares favorably to, and indeed 
exceeds that mark. Taken in the context 
of the aforementioned studies which 
show benefit of RT vs. no RT in bevaci-
zumab failure, and also that FSRT and SRS 
provide similar OS in recurrent gliomas 
before bevacizumab treatment, our data 
are consistent with these previous studies 
and moreover suggest a role for FSRT in 
the management of patients who fail 
bevacizumab. Despite our findings, it is 
worth noting that one limitation of our 
study is the potential bias of our dataset 
in that it only includes patients who are 
amenable to therapy with FSRT. There-
fore it is difficult to directly compare our 
survival data to the existing literature, 
given that the literature includes all 
patients, whether or not they are eligible 
for FSRT. Further head-to-head studies 
will be needed to evaluate FSRT versus 
other modalities to definitively establish 
a role and identify populations that would 
most benefit. 
Notably, our multivariate analysis yielded 
only one variable that was associ-
ated with overall survival: re-resection 
status. Indeed, there is controversy in 
the literature regarding the prognostic 
value of re-resection in patients with 
recurrent HGG,2 but our data suggest 
that re-resection is actually deleterious 
in terms of survival outcomes. However, 
given the retrospective nature of the 
current study, it is difficult to draw strong 
conclusions from these data, as re-resec-
tion status itself may be confounding by 
representing underlying patient charac-
teristics that lead to poorer prognosis. 
Future studies will be needed to identify 
patient populations who will most benefit 
from an FSRT regimen. 
Other limits to our study include a small 
patient cohort (36) as well as those short-
comings inherent to all retrospective 
studies including selection bias and 
potential treatment differences in a 
non-randomized study. Despite these 
potential drawbacks, this study repre-
sents, to our knowledge, the largest 
literature cohort of FSRT patients in the 
context of bevacizumab failure. More-
over, the dire prognosis of these patients 
and the paucity of data regarding their 
management underscores the relevance 
of the present study, and suggests the 
need for future prospective randomized 
trials to improve survival and positively 
impact the lives of patients with HGG.
CONCLUSIONS
Favorable outcomes were observed using 
FSRT to treat patients with recurrent HGG 
and the treatment was well tolerated. 
Prospective study is warranted to further 
evaluate the efficacy of salvage FSRT for 
patients with recurrent HGG after beva-
cizumab failure.
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